JPS6045638B2 - 錯化合物およびその製造方法 - Google Patents
錯化合物およびその製造方法Info
- Publication number
- JPS6045638B2 JPS6045638B2 JP53002839A JP283978A JPS6045638B2 JP S6045638 B2 JPS6045638 B2 JP S6045638B2 JP 53002839 A JP53002839 A JP 53002839A JP 283978 A JP283978 A JP 283978A JP S6045638 B2 JPS6045638 B2 JP S6045638B2
- Authority
- JP
- Japan
- Prior art keywords
- ascorbic acid
- complex compound
- compound
- divalent copper
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title claims description 30
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 229960005070 ascorbic acid Drugs 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 10
- 239000011668 ascorbic acid Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000010936 titanium Substances 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000003609 titanium compounds Chemical class 0.000 claims 3
- 150000001879 copper Chemical class 0.000 claims 2
- 239000000706 filtrate Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010036030 Polyarthritis Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- -1 T l2(SO4)3 Chemical class 0.000 description 1
- 229910010061 TiC13 Inorganic materials 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816/77 | 1977-01-17 | ||
| GB1816/77A GB1549524A (en) | 1977-01-17 | 1977-01-17 | Composition for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS53111056A JPS53111056A (en) | 1978-09-28 |
| JPS6045638B2 true JPS6045638B2 (ja) | 1985-10-11 |
Family
ID=9728526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53002839A Expired JPS6045638B2 (ja) | 1977-01-17 | 1978-01-17 | 錯化合物およびその製造方法 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS6045638B2 (en, 2012) |
| DE (1) | DE2801355C2 (en, 2012) |
| FR (1) | FR2377393A1 (en, 2012) |
| GB (1) | GB1549524A (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0046409A1 (en) * | 1980-08-20 | 1982-02-24 | Erwin Günther Walliczek | A process for the preparation of a solution of a cuprous complex; solutions of the cuprous complexes for use in the therapeutic treatment of the human or animal body; and a method of therapeutic treatment of a plant |
| IL63928A (en) * | 1980-10-04 | 1985-02-28 | Byk Gulden Lomberg Chem Fab | Pharmaceutical compositions comprising beta-diketone metal complexes,some such novel complexes and their preparation |
| HU183536B (en) * | 1981-08-04 | 1984-05-28 | Nitrokemia Ipartelepek | Process for preparing feed additive or feed promoting the weight increase of domestic animals |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR805335A (fr) * | 1935-10-10 | 1936-11-17 | Préparation et isolement des composés de l'acide ascorbique et de ses produits d'oxydation avec les métaux susceptibles de donner des sels complexes | |
| FR807877A (fr) * | 1935-10-10 | 1937-01-23 | Préparation et isolement de sels complexes de l'acide ascorbique et de ses produits d'oxydation |
-
1977
- 1977-01-17 GB GB1816/77A patent/GB1549524A/en not_active Expired
-
1978
- 1978-01-13 DE DE2801355A patent/DE2801355C2/de not_active Expired
- 1978-01-17 JP JP53002839A patent/JPS6045638B2/ja not_active Expired
- 1978-01-17 FR FR7801246A patent/FR2377393A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB1549524A (en) | 1979-08-08 |
| JPS53111056A (en) | 1978-09-28 |
| DE2801355C2 (de) | 1986-11-06 |
| FR2377393A1 (fr) | 1978-08-11 |
| DE2801355A1 (de) | 1978-07-20 |
| FR2377393B1 (en, 2012) | 1981-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69619117T2 (de) | Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten | |
| EP0524633B1 (en) | Pharmaceutical composition suitable for influencing the reticuloendothelial system | |
| US5006551A (en) | Composition for destroying malignant tumors | |
| JPS5942683B2 (ja) | 必須金属イオン複合体 | |
| JP2025516821A (ja) | 安定性の高い重金属除去組成物およびその用途、剤形、製造方法 | |
| JPS58501676A (ja) | 微量物質としてセレニウムをヒトに供給するための混合物、ならびに細胞培養のための培地中に器官を保存する溶液および血液成分を保存する栄養溶液におけるその使用 | |
| KR101734986B1 (ko) | 아리스몰을 유효성분으로 포함하는 섬유화 질환의 예방 또는 치료용 조성물 | |
| JPS6045638B2 (ja) | 錯化合物およびその製造方法 | |
| JP4395368B2 (ja) | 細胞殺傷活性を有するカルシウム塩 | |
| JP2003510363A (ja) | 医薬組成物及びその使用法 | |
| CN107787228A (zh) | 基于双甘氨酸螯合铁和藻酸和/或藻酸的水溶性盐的产品、其制剂及其药物用途 | |
| US7855191B2 (en) | Agent having a destructive effect on malignant tumors and method for the production thereof | |
| EP1524273A1 (de) | Verfahren zur Herstellung von trans- oder cis-Diammoniumdichlorodihydroxoplatin (IV)-Salzen und -Derivaten und ihre Verwendung zur Herstellung von pharmazeutischen Wirkstoffen | |
| US7261906B2 (en) | Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition | |
| US11548792B2 (en) | Water-soluble gold (III) complexes, methods of producing water-soluble gold (III) complexes and their use | |
| DK158226B (da) | Analogifremgangsmaade til fremstilling af en kompleks forbindelse af ascorbinsyre, trivalent titan og divalent kobber | |
| EP1523984A1 (de) | Pharmazeutische Zusammensetzung umfassend Oxoplatin, dessen Salze und Derivate | |
| JP7440730B2 (ja) | 医薬組成物及び抗骨粗鬆症薬の調製における応用 | |
| CN102049035B (zh) | 一种淀粉多糖铁复方制剂 | |
| JPS62207225A (ja) | 制癌補助剤 | |
| JP4292536B2 (ja) | 腫瘍を阻害するガリウム化合物 | |
| JPS61263925A (ja) | 制癌補助剤 | |
| EP2072046A1 (de) | Verwendung einer hydrocarbonathaltigen Zubereitung zur Prävention oder Behandlung von Herz-Kreislauf-Erkrankungen, Diabetes, Osteoporose und chronischem Nierenversagen | |
| KR20240016007A (ko) | 작약 추출물, 또는 이의 유래된 화합물을 유효성분으로 포함하는 오로라 키나아제 억제용 조성물 | |
| Abarna et al. | www. ijrap. net |